Abstracts Archive - Page 1929 of 2607 - ACR Meeting Abstracts

Abstract Number: 868 • 2015 ACR/ARHP Annual Meeting
Risk Factors for Cytomegalovirus Reactivation in Patients with Antineutrophil Cytoplasmic Antibody -Associated Vasculitis
Yuichiro Ota¹, Yuko Kaneko², Takahiko Kurasawa³, Kunihiro Yamaoka⁴, Katsuya Suzuki⁴ and Tsutomu Takeuchi⁵, ¹Division of Rheumatology, Department of Internal Medicine., Keio University School of Medicine., Tokyo, Japan, ²Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ³Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Saitama Medical Ctr, Kawagoe, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁵Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a disease entity characterized by inflammatory cell infiltration and necrosis of blood vessel walls. AAV usually needs…
Abstract Number: 869 • 2015 ACR/ARHP Annual Meeting
Lymphoma in Patients with Granulomatosis with Polyangiitis
Karin Hjorton¹, Erik Hellbacher¹, Christer Sundstrom², Eva Baeckstrom¹ and Ann Knight¹, ¹Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, ²Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden
Background/Purpose: The risk of malignancy in patients with Granulomatosis with Polyangiitis (GPA) is increased, as shown in several previous studies. The risk of lymphoma has…
Abstract Number: 870 • 2015 ACR/ARHP Annual Meeting
Development of an Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Patient-Reported Outcome Measure: Identification of Salient Themes and Candidate Questionnaire Item Development
Joanna Robson¹, Susan Ashdown², Jill Dawson³, Ebony Easley⁴, Don Gebhart⁵, Katherine Kellom⁶, Georgia Lanier⁷, Carol McAlear⁸, Nataliya Milman⁹, Jacqueline Peck¹⁰, Judy A. Shea¹¹, Gunnar Tomasson¹², Raashid Luqmani¹³, Peter F. Cronholm⁴ and Peter A. Merkel⁸, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, University of Oxford, Oxford, United Kingdom, ²NONE, Banbury, United Kingdom, ³Nuffield Department of Population Health HSRU, University of Oxford, Oxford, United Kingdom, ⁴Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, ⁵NONE, Columbus, OH, ⁶PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, United Kingdom, ⁷NONE, Framingham, MA, ⁸Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ¹⁰NONE, Oxford, United Kingdom, ¹¹Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, United Kingdom, ¹²Rheumatology Section, Boston University, Boston, MA, ¹³Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: Patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs), including granulomatosis with polyangiitis (Wegener's, (GPA), eosinophilic granulomatosis with polyangiitis (Churg-Strauss, EGPA), and microscopic polyangiitis (MPA),…
Abstract Number: 871 • 2015 ACR/ARHP Annual Meeting
Clinicians’ Perspective on Aspects of ANCA-Associated Vasculitis That Influence Patients’ Function and General Health: A Delphi Exercise Based on the International Classification of Function, Disability and Health
Nataliya Milman¹, Peter Tugwell², Annelies Boonen³ and Peter A. Merkel⁴, ¹Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ²Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada, ³Maastricht University Medical Center, Maastricht, Netherlands, ⁴Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: ANCA-associated vasculitis (AAV) is a multisystem condition that results in significant level of morbidity and functional limitations for many patients. Previous studies showed that…
Abstract Number: 872 • 2015 ACR/ARHP Annual Meeting
Work Limitations and Disability in Patients with Systemic Vasculitis
Emma Ali Bateman¹, Sherry Rohekar², Christian Pagnoux³ and Lillian Barra¹, ¹Medicine, Division of Rheumatology, Western University, London, ON, Canada, ²Western University, London, ON, Canada, ³Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Despite recent advances in the treatment of systemic vasculitis (SV), direct consequences of the disease leading to impairments in physical and mental function can…
Abstract Number: 873 • 2015 ACR/ARHP Annual Meeting
The ANCA-Vasculitis Index of Damage (AVID): Performance of a New Damage Instrument
Eli Miloslavsky^1,2, Na Lu³, Sebastian Unizony³, Hyon K. Choi³, Peter A. Merkel⁴, Philip Seo⁵, Robert F. Spiera⁶, Carol A. Langford⁷, Gary S. Hoffman⁷, Cees Kallenberg⁸, E. William St.Clair⁹, Nadia Tchao¹⁰, Fernando Fervenza¹¹, Paul A. Monach¹², Ulrich Specks¹³ and John H. Stone¹⁴, ¹Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, ²Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology, Johns Hopkins, Baltimore, MD, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology/Clin Immunol AA21, Univer Med Center Groningen, Groningen, Netherlands, ⁹Rheumatology and Immunology, Duke University, Durham, NC, ¹⁰ITN, San Francisco, CA, ¹¹Mayo Clinic, Rochester, MN, ¹²Rheumatology, Boston University School of Medicine, Boston, MA, ¹³Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN, ¹⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Damage related to active disease or its treatment is an important outcome measure in ANCA-associated vasculitis (AAV). The Vasculitis Damage Index (VDI), the principal…
Abstract Number: 874 • 2015 ACR/ARHP Annual Meeting
The Short Term Damage Burden in Vasculitis and Vasculitis Mimics As Measured By the Vasculitis Damage Index
Alberto Floris^1,2, Jan Sznajd^3,4, Katarzyna Wawrzycka-Adamczyk^1,5, Joanna Robson⁶, Anthea Craven⁷, Peter A. Merkel⁸, Richard A. Watts⁹, Raashid Luqmani³ and DCVAS investigators, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Rheumatology Unit, University Clinic, Cagliari, Italy, Monserrato, Italy, ³Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁴Jagiellonian University Medical College, Kraków, Poland, ⁵Jagiellonian University Medical College, Cracow, Poland, ⁶Rheumatology, University of Oxford, Oxford, United Kingdom, ⁷Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Rheumatology Department Ipswich Hospital, University of East Anglia, Ipswich, United Kingdom
Background/Purpose: Damage in vasculitis, which is due to both the vasculitic process itself and the complications of treatment, accumulates over time and accounts for significant…
Abstract Number: 875 • 2015 ACR/ARHP Annual Meeting
Differences in Early Damage Patterns in Various Forms of Primary Systemic Vasculitis
Katarzyna Wawrzycka-Adamczyk^1,2, Joanna Robson³, Alberto Floris^1,4, Jan Sznajd^2,5, Anthea Craven⁶, Richard A. Watts⁷, Peter A. Merkel⁸, Raashid Luqmani⁵ and DCVAS investigators, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Jagiellonian University Medical College, Kraków, Poland, ³Rheumatology, University of Oxford, Oxford, United Kingdom, ⁴Rheumatology Unit, University Clinic, Cagliari, Italy, Monserrato, Italy, ⁵Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁶Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ⁷Rheumatology Department Ipswich Hospital and University of East Anglia, Ipswich, United Kingdom, ⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Immunosuppressive agents have changed the outcome of the systemic vasculitides from invariably fatal to chronic conditions associated with damage as a result of disease,…
Abstract Number: 876 • 2015 ACR/ARHP Annual Meeting
Damage Develops Early and Is Common in Children with Chronic Systemic Vasculitis
Lorraine O'Neill¹, Marinka Twilt², Susanne Benseler³, Dirk Föll⁴, David A. Cabral⁵ and Raashid Luqmani⁶, ¹University of Oxford, Oxford, United Kingdom, ²Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Pediatrics, University of Calgary, Toronto, ON, Canada, ⁴University of Muenster, Muenster, Germany, ⁵Pediatrics/Rm K4-121, BC Children's Hospital, Vancouver, BC, Canada, ⁶Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: The chronic primary systemic vasculitides are a group of rare conditions with affected patients subject to a significant burden of morbidity from both the…
Abstract Number: 877 • 2015 ACR/ARHP Annual Meeting
Improved Survival in Granulomatosis with Polyangiitis: A Population-Based Study
Ju Ann¹, Hyon K. Choi², Sharan K. Rai³, Eric C. Sayre⁴ and J Antonio Avina-Zubieta^5,6, ¹Experimental Mediine, University of British Columbia, Richmond, BC, Canada, ²Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada, Richmond, BC, Canada, ⁵Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada, ⁶Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada
Background/Purpose: Granulomatosis with Polyangiitis (GPA) is associated with an increased risk of mortality. However, recent mortality trends in GPA are largely unknown, particularly in the…
Abstract Number: 878 • 2015 ACR/ARHP Annual Meeting
Significance of Interstitial Pneumonitis in Microscopic Polyangiitis
Kensuke Nakanishi and Mitsuyo Kinjo, Rheumatology, Okinawa Chubu Hospital, Uruma, Japan
Background/Purpose: Microscopic polyangiitis (MPA) is often associated with lung involvement, including alveolar hemorrhage and interstitial pneumonitis (IP). Clinical characteristics of IP in MPA have not…
Abstract Number: 879 • 2015 ACR/ARHP Annual Meeting
Diffuse Alveolar Hemorrhage Secondary to ANCA-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes
Rodrigo Cartin-Ceba¹, Fernando Fervenza², Steven R. Ytterberg³ and Ulrich Specks⁴, ¹Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Rheumatology Division, Mayo Clinic, Rochester, MN, ⁴Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: The interpretation of the literature on diffuse alveolar hemorrhage (DAH) secondary to ANCA-associated vasculitis (AAV) has been complicated by the small size of…
Abstract Number: 880 • 2015 ACR/ARHP Annual Meeting
Extra-Corporeal Membrane Oxygenation and Diffuse Alveolar Haemorrhage: A Single Centre Case Series and Analysis of the ELSO Database
Chai Yiing Ling¹, Thomas Simpson², Guy Glover², Chris Meadows³, Nicholas Ioannou³, Boris Lams³ and David P. D'Cruz⁴, ¹Louise Coote Lupus Unit, Guy's & St Thomas' Hospital, London, United Kingdom, ²Critical Care, Kings Health Partners, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ³Kings Health Partners, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ⁴Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom
Background/Purpose: Diffuse alveolar haemorrhage (DAH) is a rare and potentially fatal complication of the systemic vasculitides and may present directly to the intensivist as a…
Abstract Number: 881 • 2015 ACR/ARHP Annual Meeting
ANCA Associated Vasculitis with Hypocomplementemia Has More Diffuse Alveolar Hemorrhage and a Poor Prognosis
Shoichi Fukui¹, Naoki Iwamoto², Masataka Umeda², Ayako Nishino², Yoshikazu Nakashima², Tomohiro Koga², Shin-ya Kawashiri², Kunihiro Ichinose², Yasuko Hirai¹, Mami Tamai³, Hideki Nakamura¹, Tomoki Origuchi⁴ and Atsushi Kawakami¹, ¹Nagasaki University, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ³Transitional Med/Immun/Rheum, Nagasaki University, Nagasaki, Japan, ⁴Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan
Background/Purpose: ANCA associated vasculitis (AAV) is known as a systemic vasculitis with unknown etiology. Recently, relationship between AAV and complement have been shown and complement…
Abstract Number: 882 • 2015 ACR/ARHP Annual Meeting
Lung Damage in ANCA Associated Vasculitis Assessed By Vasculitis Damage Index: Recurrent Pulmonary Infections Have a Significant Contribution
Esra Aydın¹, Bahtiyar Toz², Burak Erer³, Nilufer Alpay Kanitez², Mustafa Erelel⁴, Ahmet Gocmez⁵, Ahmet Gul³, Murat Inanc³, Lale Ocal³ and Sevil Kamali³, ¹Department of Internal Medicine,, istanbul faculty of medicine, istanbul, Turkey, ²Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Department of Pulmonology, Istanbul University Istanbul Faculty of Medicine Department of Pulmonology, istanbul, Turkey, ⁵Department of Radiology, Istanbul University Istanbul Faculty of Medicine, istanbul, Turkey
Background/Purpose: Vasculitis damage index (VDI) is a validated comprehensive damage tool which has been developed as an outcome measure and consists of different types of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].